SCHEMBL24252675

SCHEMBL24252675

COc1ccc(B(O)O)cc1-c1ccc2c(N)nc(C)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 6/20 0.46
PLG P00747 1/20 0.41
F12 P00748 1/20 0.41
F11 P03951 1/20 0.41
KLKB1 P03952 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
RAD52 P43351 1/20 0.39
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HSP90AA1 P07900 1/20 0.35
MAP4K4 O95819 1/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CHEK2 O96017 1/20 0.33
FYN P06241 1/20 0.33
ADORA1 P30542 1/20 0.33
LIMK1 P53667 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451495 1.00 DHFR (0.46) DHFRPLGF12F11KLKB1
SCHEMBL26771040 0.92 DHFR (0.45) DHFRPLGF12F11KLKB1
SCHEMBL24252941 0.84 F12 (0.60) DHFRPLGF12F11KLKB1
SCHEMBL24252259 0.82 DHFR (0.42) DHFRPLGF12F11KLKB1
SCHEMBL24252269 0.79 DHFR (0.40) DHFRPLGF12F11KLKB1
Formic Acid SCHEMBL30452356 0.78 DHFR (0.39) DHFRPLGF12F11KLKB1
Formic Acid SCHEMBL25257239 0.78 DHFR (0.39) DHFRPLGF12F11KLKB1
SCHEMBL30452066 0.78 MAP4K4 (0.41) DHFRPLGF12F11KLKB1
SCHEMBL24252640 0.78 MAP4K4 (0.41) DHFRPLGF12F11KLKB1
SCHEMBL24252503 0.77 PLG (0.67) DHFRPLGF12F11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DHFR 1380/4885PLG 260/4885F12 29/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DHFR 1380/4885PLG 260/4885F12 29/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 DHFR 1380/4885PLG 260/4885F12 29/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH DHFR 4573/4885PLG 3106/4885F12 149/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 DHFR 3196/4885PLG 1433/4885F12 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.